(1-3)-β-D-Glucan vs Galactomannan antigen in diagnosing invasive fungal infections (IFIs)

Open Microbiology Journal

Volumn 6, Issue 1, 2012, Pages 70-73

  Fontana, C ^a,b   Gaziano, R ^a   Favaro, M ^a   Casalinuovo, I A ^a   Pistoia, E S ^a   Di Francesco, P ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Aspergillosis; Fungal infection; Galactomannan; Glucan; Haematological patients; Predictive factors

Indexed keywords

(1-3) BETA DEXTRO GLUCAN ANTIGEN; ANTIGEN; GALACTOMANNAN ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; SYSTEMIC MYCOSIS;

EID: 84866079675     PISSN: None     EISSN: 18742858     Source Type: Journal    
DOI: 10.2174/1874285801206010070     Document Type: Article

References (20)

1. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 2000; 79: 250-60.
2. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
3. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neu-tropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44: 402-9.
4. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalo-poulos A, Rafailidis PI, Falagas ME. β-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: a Meta-analysis. Clin Infect Dis 2011; 52: 750-70.
5. Falagas ME, Tassios PT. Enhanced and earlier detection of bacteremia and fungemia by multiplex polymerase chain reaction: how much en-hanced, how much earlier, and at what cost? Crit Care Med 2008; 36: 1660-1.
6. Reiss E, Obayashi T, Orle K, Yoshida M, Zancope-Oliveira RM. Non-culture based diagnostic tests for mycotic infections. Med Mycol 2000; 38: 147-59.
7. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008; (4): CD007394.
8. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of inva-sive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Disease Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
9. Mohr JF, Sims C, Paetznick V, et al. Prospective survey of (1-3)-β-D-glucan and its relationship to invasive candidiasis in the surgical inten-sive care unit setting. J Clin Microbiol 2011; 49: 58-61.
10. Cornillet A, Camus C, Imubona S, et al. Comparison of epidemiologi-cal, clinical and biological features of invasive aspergillosis in neutro-penic and non-neutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43: 577-84.
11. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
12. Ikemura K, Ikegami K, Shimazu T, Yoshioka T, Sugimoto T. False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. J Clin Microbiol 1989; 27: 1965-8.
13. Racil Z, Kocmanova I, Lengerova M, et al. Difficulties in using 1,3-beta-D glucan as the screening test for the early diagnosis of invasive fungal diseases in patients with hematological malignancies - high fre-quency of false positive results and their analysis. J Med Microbiol 2010; 59: 1016-22.
14. Pazos C, Pontón J, del Palacio A. Contribution of (1-3)-β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299-305.
15. McGinnis MR, Ed. Laboratory handbook of medical mycology. NY: Academic Press: 1980.
16. Oz Y, Kiraz N. Diagnostic methods for fungal infections in pediatric patients: microbiological, serological and molecular methods. Expert Rev Anti Infect Ther 2011; 9: 289-98.
17. Larone DH. Medically important fungi: a guide to identification. Part I and part II. Washington DC, USA: ASM press 1995.
18. Viscoli C, Machetti M, Cappellano P, et al. False positive galactoman-nan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-6.
19. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1-3)-β-D-glucan assay for the diagnosis of invasive fungal infections a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46: 1864-70.
20. Ostrosky-Zeichner L, Kullberg BJ, Bow EJ, et al. Early treatment of candidemia in adults: a review. Med Mycol 2011; 49: 113-20.